Association Between Persistent Treatment of Alzheimer’s Dementia and Osteoporosis Using a Common Data Model
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose: As it becomes an aging society, interest in senile diseases is increasing. Alzheimer’s dementia (AD) and osteoporosis are representative senile diseases. Various studies have reported that AD and osteoporosis share many risk factors that affect each other’s incidence. This aimed to determine if active medication treatment of AD could affect the development of osteoporosis. Methods: The Health Insurance Review and Assessment Service provided data consisting of diagnosis, demographics, prescription drug, procedures, medical materials, and healthcare resources. In this study, data of all AD patients in South Korea who were registered under the national health insurance system were obtained. The cohort underwent conversion to an Observational Medical Outcomes Partnership–Common Data Model version 5 format. Results: This study included 11,355 individuals in the good persistent group and an equal number of 11,355 individuals in the poor persistent group from the National Health Claims database for AD drug treatment. In primary analysis, the risk of osteoporosis was significantly higher in the poor persistence group than in the good persistence group (hazard ratio, 1.20 [95% confidence interval, 1.09–1.32]; p<0.001). Conclusions: We found that the good persistence group treated with anti-dementia drugs for AD was associated with a significant lower risk of osteoporosis in this nationwide study. Further studies are needed to clarify the pathophysiological link in patients with two chronic diseases.
Abstract
Background and Purpose: As it becomes an aging society, interest in senile diseases is increasing. Alzheimer’s dementia (AD) and osteoporosis are representative senile diseases. Various studies have reported that AD and osteoporosis share many risk factors that affect each other’s incidence. This aimed to determine if active medication treatment of AD could affect the development of osteoporosis. Methods: The Health Insurance Review and Assessment Service provided data consisting of diagnosis, demographics, prescription drug, procedures, medical materials, and healthcare resources. In this study, data of all AD patients in South Korea who were registered under the national health insurance system were obtained. The cohort underwent conversion to an Observational Medical Outcomes Partnership–Common Data Model version 5 format. Results: This study included 11,355 individuals in the good persistent group and an equal number of 11,355 individuals in the poor persistent group from the National Health Claims database for AD drug treatment. In primary analysis, the risk of osteoporosis was significantly higher in the poor persistence group than in the good persistence group (hazard ratio, 1.20 [95% confidence interval, 1.09–1.32]; p<0.001). Conclusions: We found that the good persistence group treated with anti-dementia drugs for AD was associated with a significant lower risk of osteoporosis in this nationwide study. Further studies are needed to clarify the pathophysiological link in patients with two chronic diseases.
참고문헌 (26)
- Donohue MC, "Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons", JAMA, 317, pp.2305~2316 (2017)
- Kwon MJ, "The occurrence of Alzheimer’s disease and Parkinson’s disease in individuals with osteoporosis : a longitudinal follow-up study using a national health screening database in Korea", Front Aging Neurosci, 13, pp.786337~ (2021)
- Fehsel K, "Comorbidity of osteoporosis and Alzheimer’s disease : is ‘AKT’-ing on cellular glucose uptake the missing link?", Ageing Res Rev, 76, pp.101592~ (2022)
- Chen YH, "Alzheimer’s disease and osteoporosis", Ci Ji Yi Xue Za Zhi, 29, pp.138~142 (2017)
- Chang KH, "Increased risk of dementia in patients with osteoporosis : a population-based retrospective cohort analysis", Age(Dordr), 36, pp.967~975 (2014)
- Buchner DM, "Falls and fractures in patients with Alzheimer-type dementia", JAMA, 257, pp.1492~1495 (1987)
- Tysiewicz-Dudek M, "Alzheimer’s disease and osteoporosis : common risk factors or one condition predisposing to the other?", Ortop Traumatol Rehabil, 10, pp.315~323 (2008)
- van Dyck CH, "Lecanemab in early Alzheimer’s disease", N Engl J Med, 388, pp.9~21 (2023)
- 박기형, "Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in Asia", Journal of Clinical Neurology, 17(3), pp.376~384 (2021), 대한신경과학회[DOI]
- 김희진, "Impact of an Education Program for Caregivers of Patients with Alzheimer's Disease on Treatment Discontinuation and Compliance in Korea", Journal of Clinical Neurology, 17(3), pp.368~375 (2021), 대한신경과학회[DOI]
- Ogunwale AN, "Acetylcholinesterase inhibitors are associated with reduced fracture risk among older veterans with dementia", J Bone Miner Res, 35, pp.440~445 (2020)
- Lee MH, "Trends in prescriptions for sedative-hypnotics among Korean adults : a nationwide prescription database study for 2011–2015", Soc Psychiatry Psychiatr Epidemiol, 54, pp.477~484 (2019)
- You SC, "Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention", JAMA, 324, pp.1640~1650 (2020)
- Hripcsak G, "Observational Health Data Sciences and Informatics(OHDSI) : opportunities for observational researchers", Stud Health Technol Inform, 216, pp.574~578 (2015)
- Yang Y, "Evaluation of electronic healthcare databases for post-marketing drug safety surveillance and pharmacoepidemiology in China", Drug Saf, 41, pp.125~137 (2018)
- Overhage JM, "Validation of a common data model for active safety surveillance research", J Am Med Inform Assoc, 19, pp.54~60 (2012)
- Sato T, "Donepezil prevents RANK-induced bone loss via inhibition of osteoclast differentiation by downregulating acetylcholinesterase", Heliyon(Lond), 1, pp.e00013~ (2015)
- Friedland RP, "Patients with Alzheimer’s disease have reduced activities in midlife compared with healthy control-group members", Proc Natl Acad Sci U S A, 98, pp.3440~3445 (2001)
- Rogers RS, "Bone loading during young adulthood predicts bone mineral density in physically active, middle-aged men", Phys Sportsmed, 38, pp.146~155 (2010)
- Baxter-Jones AD, "A longitudinal study of the relationship of physical activity to bone mineral accrual from adolescence to young adulthood", Bone, 43, pp.1101~1107 (2008)
- Nilsson M, "Previous sport activity during childhood and adolescence is associated with increased cortical bone size in young adult men", J Bone Miner Res, 24, pp.125~133 (2009)
- Michaëlsson K, "Leisure physical activity and the risk of fracture in men", PLoS Med, 4, pp.e199~ (2007)
- Van Langendonck L, "Influence of participation in high-impact sports during adolescence and adulthood on bone mineral density in middle-aged men : a 27-year follow-up study", Am J Epidemiol, 158, pp.525~533 (2003)
- Carter MI, "Physical activity and bone health", Mo Med, 111, pp.59~64 (2014)
- Nordström A, "Bone gained from physical activity and lost through detraining : a longitudinal study in young males", Osteoporos Int, 16, pp.835~841 (2005)
- Nordström A, "Sustained benefits from previous physical activity on bone mineral density in males", J Clin Endocrinol Metab, 91, pp.2600~2604 (2006)